NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
(PAR-25-447)
National Heart, Lung, and Blood Institute
This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to access TOPMed capacity to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBI’s BioData Catalyst (BDC). The overall goal is to move from simply cataloging genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine.
Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)
(PAR-25-449)
National Center for Complementary and Integrative Health
The National Center for Complementary and Integrative Health (NCCIH) announces this Notice of Funding Opportunity (NOFO) to solicit applications for research on how mind and body interventions through psychological and/or physical practices (e.g., mindfulness meditation, yoga, acupuncture, massage, and other brain- and/or body-based interventions) impact mechanisms of emotional well-being (EWB) and their associations with whole person health (WPH), consistent with the NIH priority to address the health needs of the American people and improve their well-being.
BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)
(RFA-DA-27-004)
National Institute on Drug Abuse
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
This notice of funding opportunity (NOFO) seeks applications to develop theories, models and methods (TMM) as tools that will advance a quantitative and predictive understanding of brain function across multiple scales, including behavior. Priority will be given to projects that develop novel capabilities for analyzing, integrating, and interpreting the large-scale, complex data emerging from the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and related efforts, which includes cell-type specific physiological, anatomical, connectivity, and behavioral data. Proposed experimental work must be limited to model parameter estimation and/or testing the validity of the tools being delivered. It is expected that the TMM tools developed under this NOFO will be made widely available to the neuroscience research community for their use and modification.
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
(RFA-DK-26-315)
National Institute of Diabetes and Digestive and Kidney Diseases
This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy of digital health technology approaches to the management of diabetes.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
(PAR-25-446)
National Institute on Drug Abuse
The purpose of this notice of funding opportunity (NOFO) is to seek grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including interventions to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.
